• 產(chǎn)品描述： PQR620 是一種新型的、選擇性的、口服可生物利用的、具有腦滲透性的 TORC1/2 的雙重抑制劑。PQR620 在56種淋巴瘤模型檢測(cè)中具有抗腫瘤活性，處理72小時(shí)的平均IC50值為250 nM。

• 靶點(diǎn)： TORC1(Cell-based assay):250 nM; TORC2(Cell-free assay):250 nM;mTOR

• 體內(nèi)研究：
  PQR620 has in vivo anti-lymphoma activity and in vivo synergism with the BCL2 inhibitor venetoclax. The combination of PQR620 and venetoclax have stronger in vivo anti-tumor activity than the single agents in a xenograft model of GCB-DLBCL

• 細(xì)胞實(shí)驗(yàn)： Cell lines: 56 lymphoma cell lines, ABC-DLBCL cell lines (TMD8, Ri-1), GCB-DLBCL cell lines (OCI-LY-1,SU-DHL-6, DoHH2) Concentrations: 2 μM Incubation Time: 24 h, 72 h Method: PQR620 is dissolved in dimethyl sulphoxide (DMSO) to obtain a stock concentration of 10 mM. PQR620 is assessed in a large panel of cell lines (n = 56) derived from lymphomas. Cell lines are treated with 2 μM PQR620 for 24 h or DMSO as control.

• 動(dòng)物實(shí)驗(yàn)： Animal Models: NOD-Scid mice with RI-1/SU-DHL-6 xenograft Dosages: 50 mg/kg, 100 mg/kg Administration: Oral gavage

• 參考文獻(xiàn)：
  1. Tarantelli C, et al. Cancers (Basel). 2019 Jun 4;11(6).

• 溶解性： Soluble  in  DMSO、Ethanol

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.245 ml	11.224 ml	22.448 ml
  5 mM	0.449 ml	2.245 ml	4.49 ml
  10 mM	0.224 ml	1.122 ml	2.245 ml
  50 mM	0.045 ml	0.224 ml	0.449 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *